8-K: Altria Boosts Share Buyback to $2B, Narrows 2025 EPS Guidance

Altria Group, Inc. reported its Q3 2025 financial results, expanded its share repurchase program to $2 billion, and narrowed its full-year adjusted diluted EPS guidance for 2025.

Summary

• Q3 2025 Net revenues decreased 3.0% to $6.072 billion.
• Q3 2025 Revenues net of excise taxes decreased 1.7% to $5.251 billion.
• Q3 2025 Reported diluted EPS increased 5.2% to $1.41.
• Q3 2025 Adjusted diluted EPS increased 3.6% to $1.45.
• Nine-months 2025 Net revenues decreased 3.4% to $17.433 billion.
• Nine-months 2025 Revenues net of excise taxes decreased 1.8% to $15.060 billion.
• Nine-months 2025 Reported diluted EPS decreased 27.4% to $3.45.
• Nine-months 2025 Adjusted diluted EPS increased 5.9% to $4.12.
• The Board of Directors authorized the expansion of the existing share repurchase program from $1 billion to $2 billion, expiring on December 31, 2026.
• The 2025 full-year adjusted diluted EPS guidance was narrowed to a range of $5.37 to $5.45, representing a growth rate of 3.5% to 5.0% from a base of $5.19 in 2024.
• In August, the regular quarterly dividend was increased by 3.9%, marking the 60th increase in 56 years, with a current annualized rate of $4.24 per share.
• on! PLUS was recently launched in Florida, North Carolina, and Texas in mint, wintergreen, and tobacco flavors with multiple nicotine strengths.
• Horizon submitted a combined premarket tobacco product application (PMTA) and modified risk tobacco product application (MRTP) to the FDA for Ploom and Marlboro heated tobacco sticks.
• A non-binding Global Collaboration Memorandum of Understanding (MOU) was entered into with KT&G Corporation for long-term growth opportunities in international modern oral nicotine products, U.S. non-nicotine products, and operating efficiency in traditional tobacco.

Sentiment

Score: 7

Explanation: Despite revenue declines in traditional segments and market share losses, Altria demonstrated resilience with adjusted EPS growth, a significant expansion of its share repurchase program, and a dividend increase. Strategic moves into smoke-free and non-nicotine products, coupled with narrowed and raised EPS guidance, indicate a proactive approach to evolving market dynamics and a commitment to shareholder value.

Positives

• Adjusted diluted EPS increased by 3.6% in Q3 2025 to $1.45 and by 5.9% for the first nine months to $4.12, demonstrating underlying operational strength.
• The Board authorized a significant expansion of the share repurchase program from $1 billion to $2 billion, signaling confidence and commitment to shareholder returns.
• The regular quarterly dividend was increased by 3.9% in August, marking the 60th increase in 56 years, with an annualized rate of $4.24 per share, reinforcing a strong dividend policy.
• The 2025 full-year adjusted diluted EPS guidance was narrowed, with the lower end raised, indicating increased confidence in achieving financial targets.
• The launch of on! PLUS in key markets represents progress in the smoke-free portfolio and offers a premium, differentiated oral tobacco product.
• The submission of PMTA and MRTP applications for Ploom and Marlboro heated tobacco sticks to the FDA advances the smoke-free strategy.
• The Global Collaboration MOU with KT&G opens new pathways for long-term adjacent growth in international modern oral nicotine and U.S. non-nicotine innovation.
• Adjusted OCI margins for smokeable products increased by 1.3 percentage points to 64.4% in Q3 2025 and 2.7 percentage points to 64.4% for the first nine months, reflecting pricing power and cost management.
• Adjusted OCI margins for oral tobacco products increased by 2.4 percentage points to 69.2% in Q3 2025 and 1.8 percentage points to 69.0% for the first nine months, indicating improved profitability in this segment.

Negatives

• Net revenues decreased 3.0% in Q3 2025 to $6.072 billion and 3.4% for the first nine months to $17.433 billion, primarily due to lower shipment volumes in smokeable and oral tobacco products.
• Revenues net of excise taxes decreased 1.7% in Q3 2025 to $5.251 billion and 1.8% for the first nine months to $15.060 billion.
• Reported diluted EPS decreased 27.4% for the first nine months to $3.45, primarily driven by the 2024 gain on the sale of IQOS rights and a non-cash impairment of e-vapor reporting unit goodwill in Q1 2025.
• Smokeable products segment reported domestic cigarette shipment volume decreased 8.2% in Q3 2025 and 10.6% for the first nine months, impacted by industry decline, growth of illicit e-vapor products, and retail share losses.
• Marlboro retail share of the total cigarette category decreased 1.2 share points in Q3 2025 to 40.4% and 1.1 share points for the first nine months to 40.8%.
• Oral tobacco products segment reported domestic shipment volume decreased 9.6% in Q3 2025 and 5.2% for the first nine months, driven by retail share losses and other factors.
• on! nicotine pouches' share of the nicotine pouch category decreased 4.1 share points in Q3 2025 to 15.6% and 2.1 share points for the first nine months to 16.6%, indicating increased competition.
• Total U.S. oral tobacco category share for on! nicotine pouches decreased 0.1 share point in Q3 2025 to 8.7%.
• A non-cash impairment charge of $873 million was recorded to the e-vapor reporting unit goodwill in the first nine months of 2025.
• An unfavorable federal court ruling was received in September 2025 concerning a change in the application of foreign attribution rules relevant to the investment in ABI.

Risks

• Inability to anticipate and respond to changes in adult tobacco consumer preferences and purchase behavior.
• Inability to compete effectively in a dynamic market.
• The growth of the e-vapor category, including illicit disposable e-vapor products, contributes to reductions in domestic cigarette consumption levels and shipment volume.
• The impact of illicit trade in tobacco products and the sale of products designed to avoid the regulatory framework for tobacco products.
• Failure to develop and commercialize innovative products, including tobacco products that may reduce health risks and appeal to adult tobacco consumers.
• Changes in macroeconomic and geopolitical conditions (including inflation and tariffs) that result in shifts in adult tobacco consumer disposable income and purchasing behavior, including choosing lower-priced and discount brands or products, and reductions in shipment volumes.
• Unfavorable outcomes with respect to litigation proceedings or any governmental investigations, including significant monetary and non-monetary remedies and importation bans.
• Risks associated with significant federal, state, and local government actions, including FDA regulatory actions and inaction, and various private sector actions.
• The risk that regulators, including the FDA, and courts may interpret laws, rules, and regulations applicable to operating companies' products differently.
• Increases in tobacco product-related taxes.
• Failure to complete or manage successfully strategic relationships or transactions, including acquisitions, dispositions, joint ventures, and investments in third parties, or realize the anticipated benefits of such transactions.
• Significant changes in price, availability, or quality of tobacco, other raw materials, or component parts, including as a result of changes in macroeconomic, climate, and geopolitical conditions.
• Reliance on a few significant facilities and a small number of key suppliers, distributors, and distribution chain service providers and the risks associated with an extended disruption.
• The risk that the company may be required to write down goodwill and intangible assets, including trademarks and other intellectual property, due to impairment.
• Risks associated with the Optimize & Accelerate initiative, including business continuity, internal control over financial reporting, and the ability to recognize expected savings.
• The risk that the company could decide, or be required, to recall products.
• Various risks related to health epidemics and pandemics and the measures implemented to address them.
• Inability to attract and retain a highly skilled workforce due to the decreasing social acceptance of tobacco usage, tobacco control actions, and other factors.
• Risks associated with various U.S. and foreign laws and regulations due to international business operations.
• Risks concerning a challenge to tax positions, an increase in the income tax rate, or other changes to federal or state tax laws.
• Risks associated with legal and regulatory requirements related to climate change and other environmental sustainability matters.
• Disruption and uncertainty in the credit and capital markets, including risk of losing access to these markets.
• A downgrade or potential downgrade of credit ratings.
• The impact of heightened focus by investors and other stakeholders on performance relating to corporate responsibility matters.
• The failure of information systems to function as intended, or cyber-attacks or security breaches affecting the company or key service providers/suppliers.
• Failure to comply with laws related to personal data protection, privacy, artificial intelligence, and information security.
• The risk that the expected benefits of the investment in ABI may not materialize.
• Risks associated with the investment in Cronos, including legal, regulatory, and reputational risks, and the risk that expected benefits may not materialize.

Future Outlook

Altria narrowed its 2025 full-year adjusted diluted EPS guidance to a range of $5.37 to $5.45, representing a growth rate of 3.5% to 5.0% from a 2024 base of $5.19. The company expects EPS growth to moderate in the fourth quarter due to lapping lower share count associated with the 2024 accelerated share repurchase program completion and the benefit of the Master Settlement Agreement legal fund expiration. Guidance contemplates the current estimated impact of increased tariffs on costs, assumes limited impact on combustible and e-vapor product volumes from enforcement efforts against illicit products, and that NJOY ACE does not return to the marketplace this year. It includes the reinvestment of anticipated cost savings related to the Optimize & Accelerate initiative and lower expected net periodic benefit income. The company will continue to monitor conditions related to the economy (including inflation and increased tariffs), adult tobacco consumer dynamics (including purchasing patterns and adoption of smoke-free products), illicit product enforcement, and regulatory, litigation, and legislative developments. Planned investments support the Vision, including marketplace activities for smoke-free products and continued smoke-free product research, development, and regulatory preparation expenses. The 2025 full-year adjusted effective tax rate is expected to be in a range of 23% to 24%, capital expenditures between $175 million and $225 million, and depreciation and amortization expenses approximately $290 million.

Management Comments

• "Altria continued to build significant momentum in the third quarter with exciting progress across our businesses." Billy Gifford, Altria's Chief Executive Officer.
• "Our core tobacco businesses remained resilient; we advanced our smoke-free portfolio; and we opened new pathways for long-term adjacent growth in international modern oral and U.S. non-nicotine innovation." Billy Gifford, Altria's Chief Executive Officer.
• "We also continue to demonstrate our commitment to returning value to our shareholders. In August, we announced our 60th dividend increase in 56 years, and yesterday, our Board authorized an expansion of our share repurchase program." Billy Gifford, Altria's Chief Executive Officer.
• "We are raising the lower-end of our 2025 full-year guidance and now expect to deliver adjusted diluted EPS in a range of $5.37 to $5.45." Billy Gifford, Altria's Chief Executive Officer.

Industry Context

The tobacco industry continues to face challenges from declining cigarette consumption, driven by the growth of flavored disposable e-vapor products (many believed to be illicit) and discretionary income pressures on adult tobacco consumers. Altria's strategy to 'Move Beyond Smoking' by investing in smoke-free products like on! nicotine pouches and heated tobacco (Ploom) aligns with broader industry trends towards harm reduction and diversification. The collaboration with KT&G further emphasizes a push into international modern oral nicotine and U.S. non-nicotine markets, reflecting a strategic pivot away from traditional combustibles. However, the decline in Marlboro's retail share and on!'s share within the growing nicotine pouch category indicates intense competition and evolving consumer preferences within both traditional and emerging segments.

Comparison to Industry Standards

• The estimated domestic cigarette industry volume decreased by 8% in Q3 2025 and 8.5% for the first nine months, indicating a continued secular decline in combustible tobacco, consistent with global trends in developed markets. Altria's reported cigarette shipment volume decline of 8.2% in Q3 and 10.6% YTD is slightly worse than the overall industry decline, suggesting some market share loss in addition to the industry trend.
• The U.S. nicotine pouch category grew by an estimated 14.5% for the six months ended September 30, 2025, highlighting a robust growth segment within the broader oral tobacco market. While Altria's on! brand is a significant player, its share of the nicotine pouch category decreased by 4.1 share points in Q3 2025 to 15.6%, indicating strong competition from other brands like Zyn (Philip Morris International) and potentially new entrants.
• Altria's dividend increase (60th in 56 years) and expanded share repurchase program demonstrate a strong commitment to shareholder returns, a common characteristic of mature, cash-generative companies in industries with limited organic growth, similar to other established consumer staples companies.
• The non-cash impairment charge of $873 million to the e-vapor reporting unit goodwill reflects challenges in the e-vapor market, potentially due to regulatory hurdles, illicit products, and intense competition, which has impacted other players in the e-vapor space.

Corporate Governance

Legal Proceedings

• International Trade Commission's (ITC) exclusion order and cease-and-desist orders prohibiting the importation and sale of NJOY ACE in the United States, resulting in $71 million in expenses in the first nine months of 2025.
• An unfavorable federal court ruling in September 2025 concerning a change in the application of foreign attribution rules relevant to the investment in ABI, leading to an income tax benefit from tax reserves.
• Ongoing tobacco and health and certain other litigation items, with pre-tax charges of $48 million in the first nine months of 2025.

Stakeholder Impact

• Shareholders: Positive impact from expanded share repurchase program and increased dividends, signaling commitment to returning capital. Potential for long-term growth from smoke-free and non-nicotine initiatives.
• Employees: Potential impact from the 'Optimize & Accelerate initiative' which aims for cost savings, though specific employee impacts are not detailed.
• Customers (Adult Tobacco Consumers): Introduction of new products like on! PLUS and potential availability of Ploom heated tobacco sticks offers more choices in smoke-free alternatives. Continued availability of traditional tobacco products.
• Suppliers: No direct impact mentioned, but risks related to changes in price, availability, or quality of raw materials are noted.
• Creditors: No direct impact mentioned, but the company's financial performance and commitment to shareholder returns could influence credit ratings and access to capital markets.

Next Steps

• Continue share repurchases under the expanded $2 billion program until its expiration on December 31, 2026.
• Monitor marketplace conditions and other factors for future share repurchases, which remain subject to Board discretion.
• Maintain the progressive dividend goal targeting mid-single digits dividend per share growth annually through 2028.
• Continue marketplace activities and research and development investments in support of smoke-free products.
• Monitor conditions related to the economy (inflation, tariffs), adult tobacco consumer dynamics, illicit product enforcement, and regulatory/litigation developments.
• Horizon Innovations LLC will await FDA decision on the combined PMTA and MRTP application for Ploom and Marlboro heated tobacco sticks.
• Pursue long-term growth opportunities with KT&G in international modern oral nicotine products, U.S. non-nicotine products, and operating efficiency in traditional tobacco.

Key Dates

Recommendation

Altria's Q3 2025 results show a mixed picture. While adjusted EPS growth and significant shareholder return initiatives (expanded buyback, increased dividend) are positive, the core combustible business continues to face declines in revenue and shipment volume, with Marlboro losing retail share. The non-cash impairment of e-vapor goodwill highlights challenges in the smoke-free transition. Strategic moves like on! PLUS launch and the KT&G collaboration are promising for future growth, but their impact is long-term. The narrowed EPS guidance, while raising the lower end, still reflects a dynamic and challenging external environment. Given the ongoing decline in traditional segments offset by strategic pivots and shareholder returns, a 'hold' recommendation is appropriate for investors seeking income and long-term transition potential, but who acknowledge the headwinds in the core business.

Keywords

Altria, MO, Earnings, Q3 2025, Financial Results, Share Repurchase, Dividend, EPS Guidance, Smoke-Free Products, Oral Tobacco, Cigarettes, Marlboro, on! PLUS, Ploom, KT&G, Tobacco Industry, SEC Filing